Every Form 4 that Co-Diagnostics, Inc. (CODX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.
Co-Diagnostics, Inc. Chief Executive Officer Dwight H. Egan reported compensation-related equity activity involving common stock and restricted stock units. On May 23, 2026, 1,633 common shares were disposed of at $5.07 per share in a mandated “sell to cover” transaction to satisfy tax withholding obligations tied to RSU vesting, described as not a discretionary trade by the reporting person.
On the same date, he received a grant of 4,584 common shares at no cost and exercised 4,584 restricted stock units into common stock. After these transactions, he directly holds 27,893 common shares and 9,166 restricted stock units.
Co-Diagnostics, Inc. Chief Financial Officer Brian Lee Brown reported routine equity compensation activity involving common stock and restricted stock units. On May 23, 2026, he disposed of 1,350 shares of common stock at $5.07 per share in a transaction described as required to cover tax withholding obligations through a mandated “sell to cover” election under the company’s equity plans, not a discretionary trade.
On the same date, he acquired 3,750 shares of common stock at $0.00 per share as a grant or award, tied to the vesting and settlement of restricted stock units. He also exercised 3,750 restricted stock units into common stock, with remaining derivative holdings reported as 7,500 restricted stock units following the transaction sequence. After these transactions, Brown directly held 22,379 shares of common stock. The activity reflects standard compensation vesting and tax settlement rather than open-market buying or selling.
Co-Diagnostics, Inc. president Richard David Abbott reported routine equity compensation activity involving restricted stock units. He exercised 1,890 restricted stock units into common shares at a stated price of $0.00 per share and received these as a grant or award. On the same date, 680 common shares were disposed of to the issuer at $5.07 per share to cover tax withholding obligations, as required under the company’s equity incentive plan, rather than as a discretionary trade. Following these transactions, he directly held 3,417 shares of common stock.
Co-Diagnostics, Inc. director Edward L. Murphy reported equity compensation activity. He received a grant of 1,695 shares of common stock at $0.00 per share, classified as a grant or award. On the same date, he exercised 1,695 restricted stock units into common stock. Following these transactions, he directly holds 11,084 shares of common stock and 4,000 restricted stock units, reflecting both current ownership and remaining stock-based incentives.
Co-Diagnostics, Inc. director Richard S. Serbin reported equity compensation activity involving restricted stock units. On May 23, 2026, he acquired 1,695 shares of Common Stock at $0.00 per share through a grant and related RSU conversion, rather than an open‑market purchase. After this transaction, he directly holds 10,751 Common shares and 4,000 restricted stock units. The footnotes explain these RSUs were awarded under the company’s 2015 Long Term Incentive Plan with scheduled vesting in six semiannual installments across multiple grant dates.
Co-Diagnostics, Inc. director Eugene Durenard received 1,695 shares of common stock as a stock award and vested restricted stock units that converted into the same number of shares on May 23. These compensation-related transactions were at a reported price of $0.00 per share.
After the award and RSU conversion, Durenard directly holds 10,668 shares of common stock and 4,000 restricted stock units. The RSUs relate to grants of 2,334, 3,667 and 4,167 units made in 2023, 2024 and 2025 under the company’s 2015 Long Term Incentive Plan, vesting in semiannual installments.
Co-Diagnostics, Inc. director James B. Nelson acquired 1,695 shares of Common Stock on May 23, 2026 through a stock grant with a reported price of $0.00 per share, increasing his direct holdings to 10,668 common shares. On the same date, he exercised 1,695 Restricted Stock Units into Common Stock, and the filing shows 4,000 Restricted Stock Units remaining under his direct ownership, linked to awards granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan that vest in six equal installments every six months.
Co-Diagnostics, Inc. (CODX) director equity update: A company director reported the vesting and issuance of 57,499 shares of common stock on 11/23/2025 at a stated price of $0.00, reflecting settlement of previously granted restricted stock units under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan. After this transaction, the director beneficially owns 281,666 shares of common stock and 170,834 restricted stock units. The RSUs referenced stem from awards of 40,000 units on January 17, 2023, 70,000 units on June 12, 2023, 110,000 units on April 26, 2024, and 125,000 units on August 13, 2025, each vesting in six equal installments every six months from their respective commencement dates.
Co-Diagnostics, Inc. reported an insider equity transaction by its Chief Financial Officer, Brian L. Brown. On 11/23/2025, Brown had 134,167 restricted stock units convert into common stock at an exercise price of $0.00. Following this vesting event, he beneficially owned 599,355 shares of Co-Diagnostics common stock directly.
On the same date, 40,723 shares of common stock were sold at a price of $0.35 per share. The filing explains that these shares were sold solely to cover tax withholding obligations related to the vesting of restricted stock units under the company’s long-term incentive plan and did not represent a discretionary trade by Brown.
Co-Diagnostics, Inc. reports that President Richard David Abbott exercised 56,667 restricted stock units into common stock and, on the same date, disposed of 17,200 shares back to the issuer at $0.35 per share. After these transactions, he holds 66,202 common shares directly. Footnotes note prior RSU awards of 120,000 and 220,000 units that vest in six semiannual installments and explain that certain share sales were mandated “sell to cover” transactions for tax withholding, rather than discretionary trades.
Co-Diagnostics, Inc. (CODX) reported an insider equity transaction by its Chief Executive Officer and director. On 11/23/2025, the CEO acquired 163,333 shares of common stock at $0.00 per share through the vesting and settlement of previously granted restricted stock units. On the same date, 49,575 shares of common stock were sold at $0.35 per share to cover tax withholding obligations related to this RSU vesting, as required under the company’s equity incentive plans.
Following these transactions, the CEO beneficially owned 748,252 shares of common stock directly and held 412,500 restricted stock units, each representing a contingent right to receive one share of common stock, subject to vesting schedules under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
Co-Diagnostics, Inc. (CODX) reported an equity award-related transaction by a director on 11/23/2025. The reporting person acquired 57,499 shares of common stock at a price of $0.00, reflecting the vesting and settlement of previously granted restricted stock units under the company’s 2015 Long Term Incentive Plan.
After this transaction, the director beneficially owned 271,666 shares of common stock directly and 170,834 restricted stock units. These units come from awards of 40,000, 70,000, 110,000 and 125,000 restricted stock units granted between January 17, 2023 and August 13, 2025, each vesting in six equal installments every six months starting on their respective commencement dates.
Co-Diagnostics, Inc. director reports equity award vesting and share increase. On 11/23/2025, the reporting person acquired 57,499 shares of Co-Diagnostics common stock at a price of $0.00 per share, reflecting the vesting and settlement of restricted stock units. Following this transaction, the director beneficially owns 269,166 shares of common stock directly and 170,834 restricted stock units.
The vested and remaining restricted stock units come from prior awards of 40,000, 70,000, 110,000, and 125,000 units granted between January 2023 and August 2025 under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, which vest in six equal installments every six months starting on their respective commencement dates.
Co-Diagnostics, Inc. (CODX) reported an insider equity transaction by a director on 11/23/2025 on a Form 4 filing. The director acquired 57,499 shares of common stock at a price of $0.00 per share, increasing direct beneficial ownership to 269,166 common shares after the transaction.
The activity reflects the vesting and settlement of restricted stock units granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan. These units come from prior awards of 40,000, 70,000, 110,000, and 125,000 restricted stock units, each vesting in six equal installments every six months starting on their respective commencement dates.